Impaired thiol-disulphide homeostasis in patients with axonal polyneuropathy

References

• Tourtellotte WG. Axon transport and neuropathy relevant perspectives on the etiopathogenesis of familial dysautonomia. Am J Pathol. 2016;186(3):490–499.
   Web of Science ®Google Scholar
• Román-Pintos LM, Villegas-Rivera G, Rodríguez-Carrizalez AD, et al. Diabetic polyneuropathy in type 2 diabetes mellitus: ınflammation, oxidative stress, and mitochondrial function. J Diabetes Res. 2016;2016:1–16.10.1155/2016/3425617
   Google Scholar
• Jones DP, Liang Y. Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med. 2009;47:1329–1338.10.1016/j.freeradbiomed.2009.08.021
   PubMed Web of Science ®Google Scholar
• Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47:326–332.10.1016/j.clinbiochem.2014.09.026
   PubMed Web of Science ®Google Scholar
• Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48:749–762.10.1016/j.freeradbiomed.2009.12.022
   PubMed Web of Science ®Google Scholar
• Biswas S, Chida AS, Rahman I. Redox modifications of protein–thiols: emerging roles in cell signaling. Biochem Pharmacol. 2006;71:551–564.10.1016/j.bcp.2005.10.044
   PubMed Web of Science ®Google Scholar
• Gumusyayla S, Vural G, Bektas H, et al. A novel oxidative stress marker in patients with Alzheimer’s disease: dynamic thiol-disulphide homeostasis. Acta Neuropsychiatr. 2016;4:1–6.
   Google Scholar
• Vural G, Gumusyayla S, Bektas H, et al. Impairment of dynamic thiol–disulphide homeostasis in patients with idiopathic Parkinson’s disease and its relationship with clinical stage of disease. Clin Neurol Neurosurg. 2017;153:50–55.10.1016/j.clineuro.2016.12.009
   PubMed Web of Science ®Google Scholar
• Bektas H, Vural G, Gumusyayla S, et al. Dynamic thiol-disulfide homeostasis in acute ischemic stroke patients. Acta Neurol Belg. 2016;1:1–16.
   Google Scholar
• Kundi H, Ates I, Kiziltunc E, et al. A novel oxidative stress marker in acute myocardial infarction: thiol/disulphide homeostasis. Am J Emerg Med. 2015;33(11):1567–1571.10.1016/j.ajem.2015.06.016
   PubMed Web of Science ®Google Scholar
• Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47:326–332.10.1016/j.clinbiochem.2014.09.026
   PubMed Web of Science ®Google Scholar
• Hughes RA. Regular review: peripheral neuropathy. Br Med J. 2002;324:466–469.10.1136/bmj.324.7335.466
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521–534.10.1016/S1474-4422(12)70065-0
   PubMed Web of Science ®Google Scholar
• Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120(1):1–34.10.1016/j.pharmthera.2008.05.005
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev. 2006;22(4):257–273.10.1002/(ISSN)1520-7560
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.10.1038/414813a
   PubMed Web of Science ®Google Scholar
• Russell JW, Golovoy D, Vincent AM, et al. High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 2002;16:1738–1748.10.1096/fj.01-1027com
   PubMed Web of Science ®Google Scholar
• Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114–121.10.1111/dme.2004.21.issue-2
   PubMed Web of Science ®Google Scholar
• Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770–776.10.2337/diacare.26.3.770
   PubMed Web of Science ®Google Scholar
• Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370.10.2337/dc06-1216
   PubMed Web of Science ®Google Scholar
• Sebastian RS, Cleveland LE, Goldman JD, et al. Older adults who use vitamin/mineral supplements differ from non users in nutrient intake adequacy and dietary attitudes. J Am Diet Assoc. 2007;107(8):1322–1332.10.1016/j.jada.2007.05.010
   PubMed Web of Science ®Google Scholar
• Smith AR, Shenvi SV, Widlansky M, et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004;11(9):1135–1146.10.2174/0929867043365387
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid- A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425–1433.10.1007/BF00400603
   PubMed Web of Science ®Google Scholar
• Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res. 1999;31(3):171–179.10.1080/10715769900300721
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). Diabetes Care. 1999;22(8):1296–1301.10.2337/diacare.22.8.1296
   PubMed Web of Science ®Google Scholar
• Loughrey CM, Young IS, Lightbody JH, et al. Oxidative stress in haemodialysis. Q J Med. 1994;87:679–683.
   Google Scholar
• Canaud B, Cristol JP, Morena M, et al. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999;17:99–106.10.1159/000014381
   PubMed Web of Science ®Google Scholar
• Raskin NH, Fishman RA. Neurologic disorders in renal failure. N Engl J Med. 1976;294:143–148.10.1056/NEJM197601152940306
   PubMed Web of Science ®Google Scholar
• Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med. 1988;109(2):143–153.10.7326/0003-4819-109-2-143
   PubMed Web of Science ®Google Scholar
• Guolo M, Stella AM, Melito V, et al. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int J Biochem Cell Biol. 1996;28:311–317.10.1016/1357-2725(95)00133-6
   PubMed Web of Science ®Google Scholar
• Tegnér R, Lindholm B. Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand. 1985;218:409–416.
   PubMedGoogle Scholar
• Lindsay RM, Bolton CF, Clark WF, et al. The effect of alterations of uremic retention products upon platelet and peripheral nerve function. Clin Nephrol. 1983;19:110–115.
   PubMed Web of Science ®Google Scholar
• Bansal VK, Bansal S. Nervous system disorders in dialysis patients. Handb Clin Neurol. 2014;119:395–404.10.1016/B978-0-7020-4086-3.00025-4
   PubMedGoogle Scholar
• Miyata T, van Ypersele de Strihou C, et al. Altrations in non-enzymatic biochemistry in uremia: origin and significance of ‘carbonyl stress’ in longterm uremic complications. Kidney Int. 1999;55:388–399.
   Web of Science ®Google Scholar
• Koken T, Kahraman A, Serteser M, et al. Hemodiyaliz ve oksidatif stres [Hemodialysis and oxidative stress]. Med J Kocatepe. 2004;5(1):9–13. Turkish.
   Google Scholar
• Behse F, Buchthal F. Alcoholic neuropathy: clinical, electrophysiological, and biopsy findings. Ann Neurol. 1977;2:95–110.10.1002/(ISSN)1531-8249
   Web of Science ®Google Scholar
• Nguyen VA, Le T, Tong M, et al. Experimental alcohol-related peripheral neuropathy: role of ınsulin/IGF resistance. Nutrients. 2012;4(12):1042–1057.10.3390/nu4081042
   PubMedGoogle Scholar
• Mols F, Beijers T, Vreugdenhil G, et al. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–2269.10.1007/s00520-014-2255-7
   PubMed Web of Science ®Google Scholar
• Dietrich J, Wen PY. Neurologic complications of chemotherapy. In: Schiff D, Kesari S, Wen PY, editors. Cancer neurology ın clinical practice. Totowa, NJ: Humana Press; 2008. p. 287–326.10.1007/978-1-59745-412-4
   Google Scholar
• Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63:761–767.10.1007/s00280-008-0876-6
   PubMed Web of Science ®Google Scholar
• McDonald ES, Randon KR, Knight A, et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005;18(2):305–313.10.1016/j.nbd.2004.09.013
   PubMed Web of Science ®Google Scholar
• Zhang H, Mizumachi T, Carcel-Trullols J, et al. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis. 2007;28(8):1629–1637.10.1093/carcin/bgm072
   PubMed Web of Science ®Google Scholar
• Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology. 2009;30:312–319.10.1016/j.neuro.2009.01.003
   PubMed Web of Science ®Google Scholar